Cg Oncology Inc (CGON) - News Archive

CG Oncology Completes Enrollment in PIVOT-006: A Landmark Step in Addressing Unmet Needs in Intermediate-Risk Non-Muscle Invasive Bladder Cancer In a significant advancement for urologic oncology, CG Oncology has announ...

: In recent developments within oncological therapies, particularly in the treatment of non-muscle invasive bladder cancer (NMIBC), Cretostimogene Grenadenorepvec, an innovative oncolytic immunotherapy, marks a signific...

In a recent publication in the prestigious Nature Medicine journal, CG Oncology has announced the final results from its CORE-001 study involving the use of Cretostimogene Grenadenorepvec (CG0070) in combination with Pe...

CG Oncology, a clinical-stage biopharmaceutical company, has announced the final positive results from their Phase 2 CORE-001 study evaluating the combination therapy of cretostimogene grenadenorepvec and pembrolizumab...

Cretostimogene Monotherapy Shows Remarkable 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerBladder cancer is a significant health concern globally, with non-muscle invasive...

The upcoming conference s highlight will be CG Oncology s presentation of the latest clinical trial results involving Cretostimogene and Pembrolizumab. Initial reports indicate that this combination therapy displays an...

CG Oncology, a leading biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment, is set to present new 12-month data from the Phase 3 BOND-003 trial at the upcoming AUA 2024 Annual...